***Salmonella*, *Campylobacter* and genetic characterisation**

TEST FORMS

|  |
| --- |
| Name:  Name of laboratory:  Name of institute:  City:  Country:  E-mail:  Fax: |

#### Comments:

#### 

#### **TEST FORM**

Does your laboratory have an accreditation for performing *Salmonella* AST?  Yes  No

Which method did you use for antimicrobial susceptibility testing of *Salmonella* in this EQAS:

Broth microdilution

Agar dilution

Brand of microbroth plates/agar**:**

Incubation conditions:      °C/     h

How many *Salmonella* isolates does your laboratory annually isolate:

How many *Salmonella* isolates does your laboratory annually test for antimicrobial susceptibility by a MIC method:

Which method was followed for the preparation of the inoculum (please describe)

* Which standard was followed (TREK, CLSI…)
* Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)
* Please describe in detail how you prepared the dilution of the inoculum (including the volume in final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 McFarland solution in 10ml MH broth, for an expected inoculum of 1\*105 CFU/ml)

Comments or additional information:

**TEST FORM**

Does your laboratory have an accreditation for *Campylobacter* AST?  Yes  No

Incubation conditions:  36-37ºC / 48h  42ºC / 24h

Method used for antimicrobial susceptibility testing of *Campylobacter* in this EQAS:

Broth microdilution

Agardilution

Brand of microbroth plates/agar:

How many *Campylobacter* isolates does your laboratory annually isolate:

How many *Campylobacter* isolates does your laboratory annually susceptibility test:

Which method was followed for the preparation of the inoculum (please describe)

* Which standard was followed (TREK, CLSI…)
* Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)
* Please describe in detail how you prepared the dilution of the inoculum (including the volume in final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 McFarland solution in 10ml MH broth, for an expected inoculum of 1\*105 CFU/ml)

Comments or additional information:

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.1 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.1 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.2 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.2 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.3 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.3 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.4 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.4 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.5 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.5 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.6 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.6 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.7 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.7 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.8 | Ampicillin, AMP |  |  |  |
| Azithromycin, AZI |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Chloramphenicol, CHL |  |  |  |
| Ciprofloxacin CIP |  |  |  |
| Colistin, COL |  |  |  |
| Gentamicin, GEN |  |  |  |
| Meropenem, MERO |  |  |  |
| Nalidixic acid, NAL |  |  |  |
| Sulfamethoxazole, SMX |  |  |  |
| Tetracycline, TET |  |  |  |
| Tigecycline, TGC |  |  |  |
| Trimethoprim, TMP |  |  |  |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Strain | Antimicrobial | Results and interpretation | | |
| > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 12.8 | Cefepime, FEP |  |  |  |
| Cefotaxime, FOT |  |  |  |
| Cefotaxime + clavulanic acid (F/C) |  |  |  |
| Cefoxitin, FOX |  |  |  |
| Ceftazidime, TAZ |  |  |  |
| Ceftazidime+ clavulanic acid (T/C) |  |  |  |
| Ertapenem, ETP |  |  |  |
| Imipenem, IMI |  |  |  |
| Meropenem, MERO |  |  |  |
| Temocillin, TRM |  |  |  |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| Presumptive ESBL  Presumptive ESBL+ AmpC | Presumptive AmpC  Presumptive Carbapenemase | Other phenotype  Susceptible |

#### Comments (include optional genotype or other results):

#### **TEST FORM**

Antimicrobial susceptibility testing of reference strain *E. coli* ATCC 25922

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial | MIC-value (μg/ml) |
| 1st panel | Ampicillin, AMP |  |
| Azithromycin, AZI |  |
| Cefotaxime, FOT |  |
| Ceftazidime, TAZ |  |
| Chloramphenicol, CHL |  |
| Ciprofloxacin, CIP |  |
| Colistin, COL |  |
| Gentamicin, GEN |  |
| Meropenem, MERO |  |
| Nalidixic acid, NAL |  |
| Sulfamethoxazole, SMX\* |  |
| Tetracycline, TET |  |
| Tigecycline, TGC |  |
| Trimethoprim, TMP |  |
| 2nd panel | Cefepime, FEP |  |
| Cefotaxime, FOT |  |
| Cefotaxime + clavulanic acid (F/C) |  |
| Cefoxitin, FOX |  |
| Ceftazidime, TAZ |  |
| Ceftazidime+ clavulanic acid (T/C) |  |
| Ertapenem, ETP |  |
| Imipenem, IMI |  |
| Meropenem, MERO |  |
| Temocillin, TRM |  |

\* for the testing of the *E. coli* ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3).

#### **TEST FORM**

|  |  |  |  |
| --- | --- | --- | --- |
| Strain | Antimicrobial | Interpretation | |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*  EURL C-12.1  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.2  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.3  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.4  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |

#### 

#### **TEST FORM**

|  |  |  |  |
| --- | --- | --- | --- |
| Strain | Antimicrobial | Interpretation | |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*  EURL C-12.5  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.6  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.7  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*  EURL C-12.8  *C. jejuni*  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |

#### **TEST FORM**

Susceptibility testing of *Campylobacter jejuni* reference strain ATCC 33560

|  |  |  |  |
| --- | --- | --- | --- |
| Strain | Antimicrobial | MIC-value (μg/ml) | |
| 36 °C/48 hours | 42 °C/24 hours |
| *C. jejuni* ATCC 33560 | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Nalidixic acid |  |  |
| Tetracycline |  |  |

**For Agar dilution:**

Susceptibility testing of *Campylobacter jejuni* reference strain ATCC 33560

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial | MIC-value (μg/ml) |
| *C. jejuni* ATCC 33560 | Ciprofloxacin |  |
| Erythromycin |  |
| Gentamicin |  |
| Nalidixic acid |  |
| Tetracycline |  |

#### **TEST FORM – genotypic characterisation**

Genotypic characterisation of the test strains

|  |  |
| --- | --- |
| Strain code: | Method used:  If PCR-methods, additional information should be given below |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |

|  |  |
| --- | --- |
| Strain code: | Method used:  If PCR-methods, additional information should be given below |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |
| Gene:  Found  Tested, not found | Published method , reference: |
| In-house method |
| Primer used 5’→3’: |
| Primer used 3’→5’: |

Comments: